JAPAN LIFELINE CO.

Japan Lifeline posted sales of JPY 59.18 billion in Q4 2026 (+4.6% yoy), beating expectations by 1.51%; earnings per share were JPY 133.30. Operating profit and net income rose slightly, while gross margin contracted by about 100 basis points to 59.4% due to an unfavorable product mix and cuts in reimbursement prices. Competition from new technologies such as pulsed-field ablation and margin pressure weigh on the outlook, after which the stock fell 9.85% to JPY 1,401. Management continues to emphasize innovation, expanding core products and entering new therapeutic areas, but sees risks from price and competitive pressure. » More on de.investing.com

Japan Lifeline reports for H1 FY 2026 record net sales of ¥29,285 million (+4.6%) and a net profit of ¥4,774 million (+7.7%). Drivers were a volume increase in atrial fibrillation procedures (+10%) and strong growth in new therapy areas (+38.4%), while price adjustments in the reimbursement system had a dampening effect. The company has achieved about half of its annual targets and for the first time presented an AI-CFO avatar to present the results. » More on de.investing.com

Japan Lifeline posted a record net revenue of ¥29.28 billion in Q2 2025 (+4.6%), operating income of ¥6.62 billion (+5.7%) and net profit of ¥770 million (+7.7%). Sales of in-house products fell slightly, while international sales—especially in neurovascular and gastrointestinal—were up. Revenue was marginally below expectations, so the stock rose only 0.07%. The company confirmed its full-year forecasts and continues to pursue international expansion and the rollout of PFA technology. » More on de.investing.com